Our Values
Message
Corporate Philosophy
Corporate Branding
Sawai at a Glance
Transparency
Products
Quality Policy & Feature of Each Function
ESG Data(Related Content)New Window
Sustainability
Sustainability Initiatives
Our Approach
Integrated Report(Related Content)New Window
Our Humanistic Business
Corporate Profile
Corporate History
InvestorsNew Window
Aug. 16. 2024
Sawai Receives Approvals for Six Generic Drugs with 11 Strengths
Jun. 13. 2024
Sawai Announces Listing of Two Generic Drugs with Three Strengths
Feb. 15. 2024
Sawai Receives Approvals for Three Generic Drugs with Four Strengths
Dec. 07. 2023
Sawai Announces Listing of a single Generic Drug with Two Strengths
Nov. 07. 2023
Launch of Pitavastatin tablets in the United States – Sawai’s First generic ANDA approval and launch for US market under Paragraph IV–
Jun. 15. 2023
Sawai Announces Listing of Two Generic Drugs with Eight Strengths
Feb. 15. 2023
Sawai Receives Approvals for Three Generic Drugs with 10 Strengths
Dec. 27. 2022
Sawai Pharmaceutical Applies for Marketing and Manufacturing Approval for Non-Invasive Neuromodulation Device
Dec. 08. 2022
Sawai Announces Listing of Six Generic Drugs with 12 Strengths
Aug. 16. 2022
Sawai Receives Approvals for Six Generic Drugs with 13 Strengths
Jun. 16. 2022
Sawai Announces Listing of Five Generic Drugs with 11 Strengths
Feb. 15. 2022
Sawai Receives Approvals for Seven Generic Drugs with 14 Strengths
Dec. 09. 2021
Sawai Announces Listing of Five Generic Drugs with Nine Strengths
Dec. 03. 2021
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-
Aug. 16. 2021
Sawai Receives Approvals for Four Generic Drugs with Eight Strengths
Jun. 17. 2021
Sawai Launches Eight Generic Drugs with 23 Strengths
Apr. 01. 2021
Notice of Establishment of Sawai Group Holdings
Feb. 15. 2021
Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths
Feb. 12. 2021
Sawai Reports Third Quarter FY2020 Financial Results
Dec. 16. 2020
Upsher-Smith Launches Ramelteon Tablets
Dec. 10. 2020
Sawai Launches Two Generic Drugs with 10 Strengths
Nov. 24. 2020
Notice of Convocation of an Extraordinary General Meeting of Shareholders and the Matters to be Resolved Thereat, as well as Partial Amendments to the Articles of Incorporation
Nov. 09. 2020
Sawai Reports First Half of FY2020 Financial Results
Oct. 19. 2020
Sawai Launches Dutasteride Capsules